Yen-chun Liu

Linkou Branch
Taoyuan, TNQ, Taiwan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 32 publications

Letter: Dynamic HBcrAg and HBsAg After Nucleos(t)ide Analogue Cessation: Considerations in Interpreting Predictive Performance.

Letter: Dynamic HBcrAg and HBsAg After Nucleos(t)ide Analogue Cessation: Considerations in Interpreting Predictive Performance.

Journal: Alimentary pharmacology & therapeutics
Published: May 24, 2026

Role of HBV genotype, monitoring, and events after cessation of nucleos(t)ide analogue therapy.

Role of HBV genotype, monitoring, and events after cessation of nucleos(t)ide analogue therapy.

Journal: Journal of hepatology
Published: May 13, 2026

Surface-engineered heparin- and methoxy poly(ethylene glycol)-modified gelatin microspheres for enhanced extracellular vesicle enrichment.

Surface-engineered heparin- and methoxy poly(ethylene glycol)-modified gelatin microspheres for enhanced extracellular vesicle enrichment.

Journal: International journal of biological macromolecules
Published: April 02, 2026

Simple model stratifies liver cancer risk in non-cirrhotic chronic hepatitis C patients after viral eradication.

Simple model stratifies liver cancer risk in non-cirrhotic chronic hepatitis C patients after viral eradication.

Journal: Annals of hepatology
Published: March 21, 2026

Severe hepatitis flares after antiviral withdrawal in chronic hepatitis B with lymphoma: Impact of rituximab.

Severe hepatitis flares after antiviral withdrawal in chronic hepatitis B with lymphoma: Impact of rituximab.

Journal: JHEP reports : innovation in hepatology
Published: January 19, 2026

Influence of finish line quality and axial surface location on marginal adaptation of selective laser melting fabricated copings.

Influence of finish line quality and axial surface location on marginal adaptation of selective laser melting fabricated copings.

Journal: Journal of dental sciences
Published: November 24, 2025

The incidence of hepatitis flare and hepatic decompensation after nucleos(t)ide analogue cessation in chronic hepatitis B patients.

The incidence of hepatitis flare and hepatic decompensation after nucleos(t)ide analogue cessation in chronic hepatitis B patients.

Journal: Journal of hepatology
Published: October 09, 2024

Hepatocellular Carcinoma Incidences and Risk Factors in Hepatitis C Patients: Interferon versus Direct-Acting Agents.

Hepatocellular Carcinoma Incidences and Risk Factors in Hepatitis C Patients: Interferon versus Direct-Acting Agents.

Journal: Viruses
Published: August 22, 2024

Letter: Safety after cessation of nucleos(t)ide analogue therapy in patients with chronic hepatitis B infection.

Letter: Safety after cessation of nucleos(t)ide analogue therapy in patients with chronic hepatitis B infection.

Journal: Alimentary pharmacology & therapeutics
Published: September 13, 2023

Higher end-of-treatment HBsAg levels is associated with later onset but not severe relapse in HBeAg-negative chronic hepatitis B patients stopping antivirals.

Higher end-of-treatment HBsAg levels is associated with later onset but not severe relapse in HBeAg-negative chronic hepatitis B patients stopping antivirals.

Journal: Alimentary pharmacology & therapeutics
Published: July 07, 2023

Hepatocellular carcinoma reduced, HBsAg loss increased, and survival improved after finite therapy in hepatitis B patients with cirrhosis.

Hepatocellular carcinoma reduced, HBsAg loss increased, and survival improved after finite therapy in hepatitis B patients with cirrhosis.

Journal: Hepatology (Baltimore, Md.)
Published: February 23, 2023

Editorial: considerations for expanding treatment in grey zone chronic hepatitis B patients.

Editorial: considerations for expanding treatment in grey zone chronic hepatitis B patients.

Journal: Alimentary pharmacology & therapeutics
Published: February 14, 2023
Showing 1-12 of 32

Last Updated: 09/26/2026